Compare MTRN & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTRN | LGND |
|---|---|---|
| Founded | 1931 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.0B |
| IPO Year | 2000 | 1997 |
| Metric | MTRN | LGND |
|---|---|---|
| Price | $221.54 | $306.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $303.75 | ★ $344.25 |
| AVG Volume (30 Days) | ★ 218.8K | 196.3K |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.26% | N/A |
| EPS Growth | 1178.57 | ★ 2886.36 |
| EPS | ★ 2.76 | 1.63 |
| Revenue | N/A | ★ $141,102,000.00 |
| Revenue This Year | $33.41 | $8.04 |
| Revenue Next Year | $9.16 | $31.71 |
| P/E Ratio | ★ $79.68 | $188.34 |
| Revenue Growth | N/A | ★ 29.48 |
| 52 Week Low | $109.61 | $175.89 |
| 52 Week High | $324.99 | $326.63 |
| Indicator | MTRN | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 35.18 | 54.61 |
| Support Level | $191.03 | $277.97 |
| Resistance Level | $260.28 | $318.30 |
| Average True Range (ATR) | 14.26 | 11.25 |
| MACD | -6.95 | 0.38 |
| Stochastic Oscillator | 8.01 | 69.08 |
Materion Corp offers products that include precious and non-precious specialty metals, inorganic chemicals and powders, specialty coatings, specialty engineered beryllium and copper-based alloys, beryllium composites, ceramics, and engineered clad and plated metal systems. Its segments are: Performance Materials provides beryllium and non-beryllium containing alloy systems and custom engineered parts. Electronic Materials produces chemicals, microelectronics packaging, and specialty metal products, including vapor deposition targets and preforms. Precision Optics produces thin film coatings and optical filter materials. The Other reportable segment includes unallocated corporate costs and assets. It operates in the United States, Asia, Europe, and other countries.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.